Engineers Gate Manager’s Beam Therapeutics BEAM Stock Holding History

Engineers Gate Manager’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$492K	Sell	14,333 -38,492	-73%	-$1.16M	0.01%	1525
2026 Q1	$1.26M	Buy	+52,825	New	+$1.47M	0.02%	929
2025 Q3	–	Sell	-12,980	Closed	-$221K	–	2168
2025 Q2	$221K	Sell	12,980 -49,325	-79%	-$859K	﹤0.01%	1863
2025 Q1	$1.22M	Buy	62,305 +32,495	+109%	+$851K	0.02%	956
2024 Q4	$739K	Buy	29,810 +14,804	+99%	+$378K	0.01%	1186
2024 Q3	$368K	Buy	+15,006	New	+$388K	0.01%	1535
2024 Q2	–	Sell	-23,166	Closed	-$765K	–	1922
2024 Q1	$765K	Buy	23,166 +9,072	+64%	+$283K	0.02%	969
2023 Q4	$384K	Buy	+14,094	New	+$350K	0.01%	1315
2023 Q2	–	Sell	-27,052	Closed	-$828K	–	1733
2023 Q1	$828K	Buy	+27,052	New	+$1.07M	0.03%	734
2022 Q4	–	Sell	-12,025	Closed	-$573K	–	1681
2022 Q3	$573K	Buy	+12,025	New	+$686K	0.04%	713
2022 Q2	–	Sell	-4,824	Closed	-$276K	–	1911
2022 Q1	$276K	Buy	+4,824	New	+$316K	0.01%	1452

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Engineers Gate Manager's BEAM Position: Q2 2026 in Review

Engineers Gate Manager reduced its Beam Therapeutics (BEAM) stake by 73% in Q2 2026, selling an estimated $1.16M and leaving 14,333 shares worth $492K. The position accounts for 0.01% of the portfolio, ranked #1525.

Engineers Gate Manager first reported a position in BEAM in Q1 2022 and has held it in 11 quarters since. The position peaked at $1.26M in Q1 2026. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Engineers Gate Manager held 14,333 shares of Beam Therapeutics worth $492K as of Q2 2026.
Engineers Gate Manager sold 38,492 Beam Therapeutics shares in Q2 2026, an estimated $1.16M.
Beam Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1525 holding.
Engineers Gate Manager first reported a position in Beam Therapeutics in Q1 2022 and has held it in 11 quarters since.
Engineers Gate Manager's Beam Therapeutics position peaked at $1.26M in Q1 2026.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.